A study of the relationship between Helicobacter pylori microbial susceptibility, 13C-urea breath test values

Hepato-Gastroenterology

Volumn 55, Issue 82-83, 2008, Pages 786-790

  Kawai, Takashi ^a,d   Kawakami, Kohei ^a   Kataoka, Mikinori ^b   Itoi, Takao ^b   Takei, Kazuo ^b   Moriyasu, Fuminori ^b   Takagi, Yu ^b   Aoki, Tatsuya ^b   Serizawa, Hiromi ^a   Rimbard, Emiko ^c   Noguchi, Norihisa ^c   Sasatsu, Masanori ^c  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d NONE   (Japan)

Author keywords

13C urea breath test; Drug resistance; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CARBON 13; CEFACLOR; CLARITHROMYCIN; METRONIDAZOLE; SPARAFLOXACIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DUODENUM ULCER; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STOMACH ULCER; UREA BREATH TEST;

BREATH TESTS; CARBON ISOTOPES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; UREA;

EID: 44349155315     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Azuma T, Kato T, Hirai M Ito S, Kohli Y: Diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 1996; 11:662-629.
2. 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998; 33:6-13.
3. Leung WK, Ng EK, Chan FK L, Chung SC, Sung JJ: Evaluation of three commercial enzyme-linked immunosorbent assay kits for diagnosis of Helicobacter pylori in Chinese patients. Diagn Microbiol Infect Dis 1999; 34:13-17.
4. Miwa H, Kikuchi S, Ohtaka K, Kobayashiu O, Ogihara A, Hojo M, Nagahara A, Sato N: Insufficient diagnostic accuracy of imported serological kits for Helicobacter pylori infection in Japanese population. Diagn Microbiol Infect Dis 2000; 36:95-99.
5. Kawai T, Kawakami K, Taku K, Ogihara S, Hanada Y, Moriyasu F: A new serum antibody test kit (E Plate) for evaluation of Helicobacter pylori eradication. Internal Medicine 2002; 41:780-783.
6. 13C-UBT) by the Updated Sydney Grading System of Gastritis. Hepatogastroenterology 2002; 49:576-579.
7. Matsuda M, Noda Y and Takanori Y: Utility and limitation of a method for detecting Helicobacter pylori-specific antigens in the stool. J Gastroenterol 2003; 38:222-228.
8. Bilardi C, Biagini R, Dulbecco P,Iiritano E, Gambaro C, Mele MR, Borro P, Tessieri L, Zentilin P Mansi C, Vigneri S, Savarino V: Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16:1733-1738.
9. 13C-urea breath test in patient after eradication treatments. Am J Gastroenterol 2002; 97:2756-2762.
10. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobila Susceptibility Testing; Twelfth Informational Supplement. M100-S12. Viillanova, PA: NCCLS 2002.
11. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-1131.
12. Correa P, Fox J, Fontham E, Ruiz B, Lin YP, Zavala D, Taylor N, Mackinley D, delima E, Portilla H: Helicobacter pylori and gastric carcinoma: Serum antibody prevalence in populations with contrasting cancer risks. Cancer 1990; 66:2569-2574.
13. Kawaguchi H, Haruma, K, Komoto K, Yoshihara M, Sumii K, Kajiyama G: Helicobacter pylori infection is a major risk factor for atrophic gastritis. Am J Gastroenterol 1996; 91:959-962.
14. Asaka M, Kato M, Sugiyama T,Satoh K, Kuwayama H, Fukuda Y, Fujioka T, Takemoto T, Kimura K, Shimoyama T, Shimizu K, Kobayashi S: Follow-up survey of large-scale multi-center, double-blind study of triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 2003; 38:339-347.
15. Uemura N, Mukai T, Okamoto S, Okamoto S, Yamagichi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:639-642.
16. Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T: Guidelines for the management of Helicobacter pylori infection in Japan. Helicobacter 2001; 6:177-186.
17. Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishuzuka J, Komatsu Y, Mizushima T, KAgaya H, Hige S, Takeda H, Asaka M: Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15:1479-1484.
18. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A: Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15:1023-1029.
19. Kamada T, Haruma K, Komoto K, Mihara M, Chen X, Yoshiahara M, Sumi K, Kajiyama G, Tahara K, Kawamura Y: Effects of smoking and histological severity of gastritis on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin. Helicobacter 1999; 4:204-210.
20. Kamada, T, Haruma K, Miyoshi E, Mihara M, Kitadai Y, Yoshihara M, Sumi K, Kajiyama G, Tahara K, Mukai T, Kawamura Y, Hattori N: Cetraxate, a mucosal protective agent, combined with omeprazole, amoxicillin and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment Pharmacol Ther 2000; 14:1089-1094.
21. Furuta T, Shirai N,Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishuzaki T: Effect of genotypic difference in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxycillin, and clarithromycin. Pharmacogenetics 2001; 11:341-348.
22. Poon SK, Chang CS, SU J, Lai CH, Yang CC, Chen GH, Wang WC: Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapy. Aliment Pharmacol Ther 2002; 16:291-296.
23. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N: Clarithromycin resistance, but not CYP2C19 polymorphism, has a major impact on treatment success of 7-day treatment regimen for the cure of H. pylori infection. Dis Dis Sci 2001; 46:2445-2450.
24. Rimbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M: Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect 2005; 11:307-311.
25. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarceeken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M: The status of antimicrobial resistance to Helicobacter pylori in Eastern Europe. Clin Microbiol Infect 2002; 8:388-396.
26. Kawai T, Kawakami K, Kudo T, Takei K, Moriyasu F, Takagi Y, Aoki T, Koyanagi Y, Rinbara E, Noguchi M, Sasatsu M: Resistance to antimicrobial agents in eradication of Helicobacter pylori infection. ACRT 2003; 11:129-142.
27. Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shiratori Y, Omata M: Detection of clarithromycin- resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol 2000; 38:210-214.
28. Perri F, Villani MR, Festa V, Quitadamo M, Audriulli A: Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15:1023-1029.
29. Lai YC, Yang JC, Hung SH: Pretreatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcer. World J Gastrenterol 2004; 10:991-994.
30. 13C urea breath test predict resistsnace to thetherapy in Helicobacter pylori infection. Hepatogastroenterology 2005; 52:1119-1121.
31. 13C-urea breath test for diagnosis of Helicobacter pylori infection and estimation of the severity of gastritis. Digestion 1996; 57:391-397.
32. Kobayashi, D, Eishi Y, Ohkusa T, Ishige, Suzuki T, Minami J, Takizawa T, Koike M: Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 2002; 5:305-311.
33. Moshkowitz M, Konikoff FM, Peled Y, Santo M, Hallak A, Bujanover Y, Timnoy E, Gilat T: High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 37:591-592.
34. Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ: Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 1997; 46:287-288.